Severe Pediatric Onset IBD May See New Therapy Via Three-Part Venture

Severe Pediatric Onset IBD May See New Therapy Via Three-Part Venture
Medgenics recently announced a partnership with Kyowa Hakko Kirin to develop and commercialize the company's first-in-class anti-LIGHT monoclonal antibody for severe pediatric onset inflammatory bowel disease (IBD). Plans are in the works to begin signal testing in children with the condition. Testing will occur through a joint venture that includes Dr. Robert Baldassano, Director of the Center for Pediatric IBD at The Children's Hospital of Philadelphia (CHOP). Children with IBD and other autoimmune related  diseases can carry mutations that lea
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *